This report provides a complete analysis of China Vaccine Market. China's Vaccine Market has great potential due to its vast population; so, its market size is projected to cross over US$ 9 Billion by 2025.
Vaccines are developed to address the public health needs. In China, vaccines are available through the government programmed called Expanded Program on Immunization at free for all children up to 14 years of age. However private sector vaccines such as Rabies Vaccine, Influenza Vaccine and Haemophilus Influenza Type B vaccine are also available in China but are usually paid for out-of-pocket as these are neither include in government EPI program nor government health insurance schemes.
China's vaccine market is divided into public and private vaccine market. Public market is classified by Category 1 whereas and Private vaccines included in Category 2. Vaccines in the public market are regulated by PRC government and generally given free of cost by provincial CDC whereas private vaccine market is dominating by private vaccine companies. As a result, private vaccines prices are higher. China vaccine market has faced several scandals in past couple of years which certainly hinder the vaccine market growth.
High Quality Vaccines
Growing Number of Aging Population
Increasing Government Expenditure
Affordability of Vaccines
Research and Development Capabilities
Stringent Quality Management System
Long Development Time Frame
Intensive Capital Requirement
Implementation of Two Child Policy
Improving Vaccine Provision and Access
Sectors - Vaccine Market & Doses in China
Disease Type Market - Meningococcal Meningitis, Pneumococcal and DTP Vaccine Market has significant Market Share in China Vaccine Market
On the basis of disease type, Meningococcal meningitis, Pneumococcal and DTP Vaccine market is expected to control major portion of China vaccine market. Vaccine market in China is segmented into Meningococcal meningitis, Pneumococcal, DTP, Ebola, Rabies & Others.
Products - PCV13 Drives Vaccine Market in China
In terms of products, PCV13 hold the maximum share of the China vaccine market. It is predicted that PCV13 will maintain their leading place during the forecasting period as well. Products included in this report are as follows:
MPSV2 and Men A
Public and Private Vaccine Market & Doses
This report provides the detailed analysis of public and private vaccine market in China. Report also provides private and public vaccine doses in China.
All the companies covered in the report has been covered from the following points:
Key companies covered:
Sinopharm Group (China National Biotec Group Company Limited)